Related Experiment Video
Updated: Aug 23, 2026

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis
Published on: February 10, 2023
Venous thromboembolism in pediatrics
1Hematology, Hospital for Sick Children, Toronto, Ontario, Canada.
Insights
Pediatric venous thromboembolism (VTE) is a growing concern, often linked to serious illnesses and central venous lines (CVLs). Low molecular weight heparin (LMWH) is a preferred treatment due to its advantages over unfractionated heparin (UFH).
Area of Science:
- Pediatric Thrombosis
- Vascular Medicine
- Hematology
Background:
- Pediatric venous thromboembolism (VTE) is an increasingly recognized cause of significant morbidity and mortality in children.
- VTE in children is often associated with serious underlying conditions like cancer, chronic total parenteral nutrition (TPN) dependency, or congenital heart disease.
- Infants and adolescents are particularly at risk, with central venous lines (CVLs) being the most significant risk factor.
Purpose of the Study:
- To review the current understanding of pediatric VTE, including incidence, risk factors, diagnosis, treatment, and complications.
- To highlight the advantages of low molecular weight heparin (LMWH) over unfractionated heparin (UFH) in pediatric VTE management.
- To discuss the acute and long-term morbidities associated with VTE in children.
Main Methods:
- Literature review of studies on pediatric venous thromboembolism.
- Analysis of diagnostic methods, including venography and ultrasound.
- Evaluation of treatment protocols involving unfractionated heparin (UFH) and low molecular weight heparin (LMWH).
Main Results:
- The incidence of pediatric VTE varies based on study design and diagnostic methods.
- Central venous lines (CVLs) are the primary risk factor for VTE in pediatric patients.
- Low molecular weight heparin (LMWH) offers advantages in administration, monitoring, bioavailability, and half-life compared to UFH.
Conclusions:
- Pediatric VTE is a serious condition requiring careful management, with CVLs being a major risk factor.
- LMWH is a favorable treatment option for uncomplicated pediatric VTE due to its practical advantages.
- While death from VTE is rare, acute and long-term complications such as pulmonary embolism and postthrombotic syndrome can significantly impact children's health.
Abstract:
Venous thromboembolism (VTE) in pediatrics is quickly becoming a well-recognized cause of significant morbidity and mortality in children. Most children diagnosed with VTE have a serious underlying primary illness such as cancer, chronic total parenteral nutrition (TPN) dependency, or congenital heart disease. Infants and adolescents are most at risk of developing VTE, and the most significant risk factor is the presence of a central venous line (CVL). The incidence of VTE varies widely with study design and the diagnostic test used to detect thrombosis. Venography remains the gold standard diagnostic test, although ultrasound is increasingly used due to its noninvasive nature, despite concern regarding the sensitivity in upper system VTE. The treatment of uncomplicated VTE in children consists primarily of unfractionated heparin (UFH) initially, followed by oral anticoagulation or low molecular weight heparin (LMWH) for 3 months. LMWH offers many advantages over UFH due to the longer half-life, increased bioavailability, and ease of administration and monitoring in children. Acute complications of VTE in children are numerous and include pulmonary embolism (PE), chylothorax, and superior vena cava syndrome. Long-term morbidity includes recurrent VTE, postthrombotic syndrome, repeat general anesthetics for CVL placement, and eventual destruction of the upper venous system in children with repeat CVL-related VTE. Death from VTE is rare and is primarily due to PE.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis I: Introduction
Venous Thrombosis IV: Nursing Management